DAWN
Day One Biopharmaceuticals, Inc. [DAWN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DAWN Stock Summary
Top 10 Correlated Stocks
DAWN
In the News
DAWN Financial details
Company Rating
Neutral
Market Cap
1.2B
Income
-181.9M
Revenue
560K
Book val./share
3.97
Cash/share
4.2
Dividend
-
Dividend %
-
Employees
155
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-7.68
Forward P/E
-
PEG
-6.46
P/S
-
P/B
-3.08
P/C
3.54
P/FCF
-8.76
Quick Ratio
16.57
Current Ratio
16.57
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
-
EPS next Q
-
EPS this Y
17.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.81%
-
-
-
-
SMA20
-
SMA50
-
SMA100
25%
Inst Own
79.37%
Inst Trans
0.73%
ROA
-39%
ROE
-1546%
ROC
-0.49%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.67-17.85
52W High
-12.59%
52W Low
+65.11%
RSI
51
Rel Volume
1.66
Avg Volume
636.27K
Volume
1.06M
Perf Week
5.69%
Perf Month
-4.5%
Perf Quarter
46.12%
Perf Half Y
41.73%
-
-
-
-
Beta
-1.481
-
-
Volatility
0.74%, 0.75%
Prev Close
-5.65%
Price
14.86
Change
0%
DAWN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.24 | -0.65 | -1.14 | -2.02 | -2.37 | |
| Operating cash flow per share | -0.07 | -0.22 | -0.78 | -1.68 | -1.84 | |
| Free cash flow per share | -0.07 | -0.22 | -0.91 | -1.68 | -1.88 | |
| Cash per share | 0.44 | 0.71 | 4.59 | 5.23 | 4.59 | |
| Book value per share | -0.17 | -0.88 | -2.06 | -4.12 | 4.34 | |
| Tangible book value per share | -0.08 | -0.78 | 4.54 | 5.07 | 4.34 | |
| Share holders equity per share | -0.17 | -0.88 | -2.06 | -4.12 | 4.34 | |
| Interest debt per share | 0.03 | 0.01 | 0 | 0.08 | 0.01 | |
| Market cap | 1.46B | 1.46B | 1.04B | 1.41B | 1.16B | |
| Enterprise value | 1.43B | 1.41B | 759.81M | 1.32B | 934.31M | |
| P/E ratio | -98.93 | -35.93 | -14.82 | -10.66 | -6.17 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -322.33 | -107.89 | -21.51 | -12.82 | -7.93 | |
| PFCF ratio | -322.33 | -107.16 | -18.46 | -12.82 | -7.76 | |
| P/B Ratio | -136.36 | -26.85 | -8.19 | -5.22 | 3.36 | |
| PTB ratio | -136.36 | -26.85 | -8.19 | -5.22 | 3.36 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -95.79 | -103.38 | -10.45 | -9.02 | -4.54 | |
| EV to operating cash flow | -316.28 | -104.68 | -15.65 | -12.05 | -6.36 | |
| EV to free cash flow | -316.28 | -103.97 | -13.44 | -12.05 | -6.23 | |
| Earnings yield | -0.01 | -0.03 | -0.07 | -0.09 | -0.16 | |
| Free cash flow yield | 0 | -0.01 | -0.05 | -0.08 | -0.13 | |
| Debt to equity | 0 | -0.01 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0.01 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.83 | 3.17 | 3.91 | 0.57 | 1.12 | |
| Current ratio | 13.53 | 22.58 | 33.43 | 20.94 | 12.72 | |
| Interest coverage | -7.18 | -459.4 | -18.19K | -30.95 | 0 | |
| Income quality | 0.27 | 0.31 | 0.67 | 0.77 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0.16 | 0 | 0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -0.59 | -40.2 | -0.05 | -8.42 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.96 | 3.59 | 7.26 | 13.68 | 15.21 | |
| ROIC | 1.21 | 0.24 | 0.55 | 0.51 | -0.59 | |
| Return on tangible assets | -0.54 | -0.89 | -0.24 | -0.38 | -0.5 | |
| Graham Net | -0.08 | -0.81 | 4.45 | 4.97 | 4.22 | |
| Working capital | 25.32M | 43.08M | 280.71M | 331.26M | 345.77M | |
| Tangible asset value | -5.19M | -48.5M | 281.15M | 332.04M | 346.54M | |
| Net current asset value | -5.19M | -49.09M | 280.7M | 330.85M | 345.77M | |
| Invested capital | 0 | -0.01 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 135.5K | 973K | 1M | 1.42M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 475.68 | 3.2K | 178.72 | 2.45K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.77 | 0.11 | 2.04 | 0.15 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 1.38 | 0.75 | 0.55 | 0.49 | -0.55 | |
| Capex per share | 0 | 0 | -0.13 | 0 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.01 | |
| Net income per share | -0.47 | -0.49 | -0.61 | -0.54 | -0.62 | |
| Operating cash flow per share | -0.48 | -0.36 | -0.57 | -0.43 | -0.47 | |
| Free cash flow per share | -0.48 | -0.36 | -0.57 | -0.47 | -0.47 | |
| Cash per share | 4.66 | 4.42 | 5.91 | 4.72 | 4.2 | |
| Book value per share | 4.52 | -4.34 | 5.68 | -4.7 | 3.97 | |
| Tangible book value per share | 4.52 | 4.17 | 5.68 | -4.7 | 3.97 | |
| Share holders equity per share | 4.52 | -4.34 | 5.68 | -4.7 | 3.97 | |
| Interest debt per share | 0.05 | -0.04 | 0.01 | 0.01 | 0.04 | |
| Market cap | 1.58B | 962.28M | 895.08M | 1.05B | 1.27B | |
| Enterprise value | 1.5B | 913.73M | 706.49M | 813.97M | 1.04B | |
| P/E ratio | -11.35 | -6.8 | -4.88 | -5.71 | -5.84 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 2.27K | |
| POCF ratio | -44.77 | -37.03 | -21.09 | -28.45 | -30.78 | |
| PFCF ratio | -44.77 | -37 | -21.02 | -26.3 | -30.78 | |
| P/B Ratio | 4.76 | -3.08 | 2.1 | -2.61 | 3.67 | |
| PTB ratio | 4.76 | -3.08 | 2.1 | -2.61 | 3.67 | |
| EV to sales | 0 | 0 | 0 | 0 | 1.86K | |
| Enterprise value over EBITDA | -35.16 | -18.53 | -13.44 | -15.82 | -16.19 | |
| EV to operating cash flow | -42.38 | -35.16 | -16.65 | -21.96 | -25.21 | |
| EV to free cash flow | -42.38 | -35.13 | -16.59 | -20.3 | -25.21 | |
| Earnings yield | -0.02 | -0.04 | -0.05 | -0.04 | -0.04 | |
| Free cash flow yield | -0.02 | -0.03 | -0.05 | -0.04 | -0.03 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.98 | 0.98 | 3.59 | 4.68 | 3.58 | |
| Current ratio | 20.94 | 14.11 | 18.35 | 16.57 | 12.72 | |
| Interest coverage | -16.07 | 13.25 | 0 | 0 | -17.19 | |
| Income quality | 0.88 | 0.61 | 0.93 | 0.8 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 39.59 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 66.69 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.08 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.01 | |
| Capex to depreciation | 0 | -0.29 | -1.62 | -30.72 | -0.08 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 19.31 | |
| Graham number | 6.94 | 6.92 | 8.84 | 7.54 | 7.47 | |
| ROIC | -0.11 | 0.12 | -0.11 | 0.13 | -0.2 | |
| Return on tangible assets | -0.1 | -0.11 | -0.1 | -0.11 | -0.14 | |
| Graham Net | 4.43 | 4.1 | 5.58 | -4.8 | 3.86 | |
| Working capital | 331.26M | 299.54M | 425.27M | 381.06M | 345.77M | |
| Tangible asset value | 332.04M | 300.42M | 426.05M | -404.07M | 346.54M | |
| Net current asset value | 330.85M | 299.24M | 425.08M | -412.72M | 345.77M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.12M | 2.46M | 4.61M | 3.98M | 2.98M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 130 | 4.71K | 4.47K | 3.08K | 828 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.69 | 0.02 | 0.02 | 0.03 | 0.11 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.1 | 0.11 | -0.11 | 0.11 | -0.16 | |
| Capex per share | 0 | 0 | 0 | -0.04 | 0 |
DAWN Frequently Asked Questions
What is Day One Biopharmaceuticals, Inc. stock symbol ?
Day One Biopharmaceuticals, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol DAWN
What is Day One Biopharmaceuticals, Inc. stock quote today ?
Day One Biopharmaceuticals, Inc. stock price is $14.86 today.
Is Day One Biopharmaceuticals, Inc. stock public?
Yes, Day One Biopharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 636.27K
- Market Capitalization 1.2B
- Employee 155
- CEO Dr. Jeremy Bender M.B.A., Ph.D.
- Headquarters South San Francisco,CA,US
- IPO Date 2021-05-27
-
Website
https://dayonebio.com 
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
